Reformulation and drop size of apraclonidine hydrochloride

M. J. Vocci, Alan L. Robin, J. C. Wahl, P. Mayer, A. Graves, B. York, C. Enger, J. Sutton

Research output: Contribution to journalArticle

Abstract

We performed a prospective, double-masked, placebo-controlled, six-period, crossover study in which normal subjects were randomly assigned to treatment and compared three different formulations of apraclonidine hydrochloride (the present commercially available formulation, and formulations with hydroxypropylmethylcellulose or lysolecithin). We also evaluated the efficacy of a 16-μl and 30-μl drop size. The magnitude and duration of decrease in intraocular pressure was comparable for all formulations. Most subjects tolerated all formulations well with only a few reporting any side effects. The best-tolerated formulation was 0.5% apraclonidine hydrochloride delivered with a 16-μl drop size. Dry mouth developed frequently with the commercially available 1% apraclonidine solution. Blurred vision complicated the use of the formulation containing hydroxypropylmethylcellulose. Both dry mouth (P <.05) and blurred vision (P = .004) were statistically significant side effects.

Original languageEnglish (US)
Pages (from-to)154-160
Number of pages7
JournalAmerican Journal of Ophthalmology
Volume113
Issue number2
StatePublished - 1992
Externally publishedYes

Fingerprint

Mouth
Lysophosphatidylcholines
Intraocular Pressure
Cross-Over Studies
Placebos
apraclonidine
Hypromellose Derivatives
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Vocci, M. J., Robin, A. L., Wahl, J. C., Mayer, P., Graves, A., York, B., ... Sutton, J. (1992). Reformulation and drop size of apraclonidine hydrochloride. American Journal of Ophthalmology, 113(2), 154-160.

Reformulation and drop size of apraclonidine hydrochloride. / Vocci, M. J.; Robin, Alan L.; Wahl, J. C.; Mayer, P.; Graves, A.; York, B.; Enger, C.; Sutton, J.

In: American Journal of Ophthalmology, Vol. 113, No. 2, 1992, p. 154-160.

Research output: Contribution to journalArticle

Vocci, MJ, Robin, AL, Wahl, JC, Mayer, P, Graves, A, York, B, Enger, C & Sutton, J 1992, 'Reformulation and drop size of apraclonidine hydrochloride', American Journal of Ophthalmology, vol. 113, no. 2, pp. 154-160.
Vocci MJ, Robin AL, Wahl JC, Mayer P, Graves A, York B et al. Reformulation and drop size of apraclonidine hydrochloride. American Journal of Ophthalmology. 1992;113(2):154-160.
Vocci, M. J. ; Robin, Alan L. ; Wahl, J. C. ; Mayer, P. ; Graves, A. ; York, B. ; Enger, C. ; Sutton, J. / Reformulation and drop size of apraclonidine hydrochloride. In: American Journal of Ophthalmology. 1992 ; Vol. 113, No. 2. pp. 154-160.
@article{43b776896aef418b9f789c7b513249a5,
title = "Reformulation and drop size of apraclonidine hydrochloride",
abstract = "We performed a prospective, double-masked, placebo-controlled, six-period, crossover study in which normal subjects were randomly assigned to treatment and compared three different formulations of apraclonidine hydrochloride (the present commercially available formulation, and formulations with hydroxypropylmethylcellulose or lysolecithin). We also evaluated the efficacy of a 16-μl and 30-μl drop size. The magnitude and duration of decrease in intraocular pressure was comparable for all formulations. Most subjects tolerated all formulations well with only a few reporting any side effects. The best-tolerated formulation was 0.5{\%} apraclonidine hydrochloride delivered with a 16-μl drop size. Dry mouth developed frequently with the commercially available 1{\%} apraclonidine solution. Blurred vision complicated the use of the formulation containing hydroxypropylmethylcellulose. Both dry mouth (P <.05) and blurred vision (P = .004) were statistically significant side effects.",
author = "Vocci, {M. J.} and Robin, {Alan L.} and Wahl, {J. C.} and P. Mayer and A. Graves and B. York and C. Enger and J. Sutton",
year = "1992",
language = "English (US)",
volume = "113",
pages = "154--160",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Reformulation and drop size of apraclonidine hydrochloride

AU - Vocci, M. J.

AU - Robin, Alan L.

AU - Wahl, J. C.

AU - Mayer, P.

AU - Graves, A.

AU - York, B.

AU - Enger, C.

AU - Sutton, J.

PY - 1992

Y1 - 1992

N2 - We performed a prospective, double-masked, placebo-controlled, six-period, crossover study in which normal subjects were randomly assigned to treatment and compared three different formulations of apraclonidine hydrochloride (the present commercially available formulation, and formulations with hydroxypropylmethylcellulose or lysolecithin). We also evaluated the efficacy of a 16-μl and 30-μl drop size. The magnitude and duration of decrease in intraocular pressure was comparable for all formulations. Most subjects tolerated all formulations well with only a few reporting any side effects. The best-tolerated formulation was 0.5% apraclonidine hydrochloride delivered with a 16-μl drop size. Dry mouth developed frequently with the commercially available 1% apraclonidine solution. Blurred vision complicated the use of the formulation containing hydroxypropylmethylcellulose. Both dry mouth (P <.05) and blurred vision (P = .004) were statistically significant side effects.

AB - We performed a prospective, double-masked, placebo-controlled, six-period, crossover study in which normal subjects were randomly assigned to treatment and compared three different formulations of apraclonidine hydrochloride (the present commercially available formulation, and formulations with hydroxypropylmethylcellulose or lysolecithin). We also evaluated the efficacy of a 16-μl and 30-μl drop size. The magnitude and duration of decrease in intraocular pressure was comparable for all formulations. Most subjects tolerated all formulations well with only a few reporting any side effects. The best-tolerated formulation was 0.5% apraclonidine hydrochloride delivered with a 16-μl drop size. Dry mouth developed frequently with the commercially available 1% apraclonidine solution. Blurred vision complicated the use of the formulation containing hydroxypropylmethylcellulose. Both dry mouth (P <.05) and blurred vision (P = .004) were statistically significant side effects.

UR - http://www.scopus.com/inward/record.url?scp=0026513736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026513736&partnerID=8YFLogxK

M3 - Article

C2 - 1347973

AN - SCOPUS:0026513736

VL - 113

SP - 154

EP - 160

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 2

ER -